secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001213900-24-060121
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell reports preliminary Q2 sales of $5.47M, up 55% YoY; H1 sales up 82%
----------------------------------------------------------------------------

- Q2 2024 preliminary sales $5.47M vs $3.53M in Q2 2023, a 55% increase.
- Six-month sales $12.73M, up 82% from $6.98M; twelve-month sales $23.22M, up 48%.
- Backlog of orders as of June 30, 2024: approx. $8.93M.
- Production output at 74% of $30M full capacity in Q2; goal to produce $14M in H2 to reach ~95%.
- Still working on FDA approval for Re-Tain; expect fourth CMC submission after manufacturer issues resolved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390024060121/0001213900-24-060121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390024060121/ea0209162-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-060121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer